India’s pharmaceutical sector is at a tipping point. Long celebrated as the “pharmacy of the world,” the country is now pivoting from being a volume-driven generics powerhouse to becoming a hub for deep-tech, biology-based innovation. The launch of Nucelion Therapeutics Pvt Ltd, a wholly owned subsidiary of Bharat Biotech International Ltd. (BBIL), marks a significant milestone in this transition.
From Vaccines to Cell and Gene Therapies
Bharat Biotech, best known globally for its vaccine innovation—including Covaxin—has now entered the fast-evolving world of cell and gene therapy through its new Contract Research, Development and Manufacturing Organisation (CRDMO).
Free Membership Required
You must be a Free member to access this content.
Already a member? Log in here
